Standout Papers

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myelo... 2018 2026 2020 2023 1.1k
  1. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia (2018)
    Courtney D. DiNardo, Keith W. Pratz et al. Blood
  2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study (2018)
    Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology
  3. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study (2019)
    Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology

Immediate Impact

3 from Science/Nature 58 standout
Sub-graph 1 of 21

Citing Papers

Cell death
2024 Standout
Nanomedicine Tumor Targeting
2024 Standout
2 intermediate papers

Works of Tu Xu being referenced

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
2018 Standout
Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy
2018
and 2 more

Author Peers

Author Last Decade Papers Cites
Tu Xu 1848 1257 423 481 27 2.3k
Robert Schoch 1694 954 271 594 21 2.2k
Hartmut Doehner 1831 795 396 560 32 2.2k
Jonathan Kell 1882 1124 543 384 54 2.4k
John A. Liu Yin 2024 824 640 515 43 2.6k
Lars Möllgård 1457 906 519 616 40 2.2k
Erin P. Demakos 1378 1002 211 468 30 1.9k
Hussain I. Saba 1802 1532 681 581 45 3.1k
Catherine P. Leith 1380 911 1001 351 38 2.3k
Christian Wuchter 1064 1032 487 364 20 1.9k
Relja Popovic 1465 2265 392 319 40 2.9k

All Works

Loading papers...

Rankless by CCL
2026